• Journal of the Korea Academia-Industrial cooperation Society
• /
• v.15 no.8
• /
• pp.5124-5130
• /
• 2014

Dilution of the contrast agent by analyzing the change in the signal intensity during MR angiography in accordance with the viscosity and osmotic pressure minimizes the side effects, and improves the image quality. The contrast agent molarity changes by the dilution of the contrast agent in the blood, as it is injected, which leads to a change in signal intensity. Based on this principle, a phantom was prepared and experiments were performed. After the phantom experiment, a clinical experiment was conducted using the results of the phantom experiment. From November 2013 to January 2014, a group of patients were classified into diluted contrast agent (30 persons) and undiluted (30 persons), and the signal intensity of the cerebral vessels was compared. The signal intensity of the phantom according to the molarity of the contrast agent increased sharply from 0.0125 mmol, reached a peak at 20 mmol, and achieved equilibrium from 200 mmol. Based on the study results, the signal intensity of the blood vessels in the brain through were compared in a clinical experiment. All the brain vessels in the imaging range with diluting a high content of the gadolinium contrast agent showed high signal intensity. This result supports the phantom experiment and means that using the 500mmol diluted contrast agent is better than using 1000mmol undiluted contrast agent because it is easier to approach the 20mmol level needed to achieve the highest signal intensity. This study has significance in that it can minimize the high viscosity and osmotic pressure, which can cause side effects and improve the image quality using the method of the dilution rate.

• Investigative Magnetic Resonance Imaging
• /
• v.8 no.1
• /
• pp.32-41
• /
• 2004

Purpose : To measure the NMR relaxation properties of MnPC, to observe the characteristics of liver enhancement patterns on MR images in experimentally implanted rabbit VX2 tumor model, and to estimate the possibility of tissue specific contrast agent for MnPC in comparison with the hepatobiliary agent. Materials and Methods : Phthalocyanine (PC) was chelated with paramagnetic ions, manganese (Mn). 2.01 g (5.2 mmol) of phthalocyanine was mixed with 0.37 g (1.4 nlmol) of Mn chloride at $310^{\circ}C$ for 36 hours and then purified by chromatography ($CHCl_3:\;CH_3OH=98:2$, volume ratio) to obtain 1.04 g $(46\%)$ of MnPC (molecular weight = 2000 daltons). The T1/T2 relaxivity (R1/R2) for MnPC were determined at a 1.5 T (64 MHz) MR spectrometer. VX2 tumor model was experimentally implanted in the liver parenchyma of rabbits. All MR studies were performed on 1.5 T. The human extremity radio frequency coil of a bird cage type was employed. MR images were acquired at 17 to 24 days after VX2 carcinoma implantation.4 mmol/kg MnPC and 0.01 mmol/kg Mn-DPDP were injected via the ear vein of rabbits. T1-weighted images were obtained with spin-echo (TR/TE=516/14 msec) and fast multiplanar spoiled gradient recalled (TR/TE : 80/4 msec, $60^{\circ}$ flip angle) pulse sequence. Fast spin-echo (TR/TE=1200/85 msec) was used to obtain the T2-weighted images. Results : The value of T1/T2 relaxivity (R1/R2) of MnPC was $7.28\;mM^{-1}S^{-1}$ and $55.56\;mM^{-1}S^{-1}$ respectively at 1.5 T (64 MHz). Because the T2 relaxivity of MnPC that bonded strongly, covalently manganese with phthalocyanine was very high, the signal intensity of liver parenchyma was decreased on postcontrast T2-weighted images and we could easily distinguish the VX2 carcinoma within the liver parenchyma. When MnPC was administrated intravenously, the tumor margin delineation was more remarkable than Mn-DPDP-enhanced images. The enhancement of liver parenchyma with MnPC persisted at relatively high levels over at least one hour after injection of the contrast agents. Conclusion : The hepatic uptake and biliary excretion of MnPC, which are similar to Mn-DPDP, suggest that this agent is a new liver-specific agent. Also, MnPC seems to be used as a dual contrast agent (T1 and T2) with high T2 relaxivity. However, it is warranted that MnPC needs further investigation as a potential contrast agent for MR imaging of the liver. That is, further characterizations of MnPC are needed in vivo and in vitro before clinical trials. The diagnostic potential of MnPC will also have to be examined more in the animal models of additional types.